vs
Side-by-side financial comparison of Gossamer Bio, Inc. (GOSS) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
WEST BANCORPORATION INC is the larger business by last-quarter revenue ($26.9M vs $13.8M, roughly 2.0× Gossamer Bio, Inc.). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -342.3%, a 381.6% gap on every dollar of revenue. On growth, Gossamer Bio, Inc. posted the faster year-over-year revenue change (47.1% vs 16.6%).
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
GOSS vs WTBA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $26.9M |
| Net Profit | $-47.2M | $10.6M |
| Gross Margin | — | — |
| Operating Margin | -333.6% | 50.0% |
| Net Margin | -342.3% | 39.2% |
| Revenue YoY | 47.1% | 16.6% |
| Net Profit YoY | -43.0% | 34.8% |
| EPS (diluted) | $-0.21 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | $13.8M | $24.2M | ||
| Q3 25 | $13.3M | $25.0M | ||
| Q2 25 | — | $23.8M | ||
| Q1 25 | — | $23.1M | ||
| Q4 24 | — | $20.9M | ||
| Q3 24 | — | $20.3M | ||
| Q2 24 | $95.8M | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | $-47.2M | $7.4M | ||
| Q3 25 | $-48.2M | $9.3M | ||
| Q2 25 | — | $8.0M | ||
| Q1 25 | — | $7.8M | ||
| Q4 24 | — | $7.1M | ||
| Q3 24 | — | $6.0M | ||
| Q2 24 | $49.2M | $5.2M |
| Q1 26 | — | 50.0% | ||
| Q4 25 | -333.6% | 39.6% | ||
| Q3 25 | -369.4% | 45.8% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | — | 43.4% | ||
| Q4 24 | — | 30.9% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | 54.3% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | -342.3% | 30.7% | ||
| Q3 25 | -362.7% | 37.3% | ||
| Q2 25 | — | 33.5% | ||
| Q1 25 | — | 34.0% | ||
| Q4 24 | — | 34.0% | ||
| Q3 24 | — | 29.3% | ||
| Q2 24 | 51.4% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | $-0.21 | $0.44 | ||
| Q3 25 | $-0.21 | $0.55 | ||
| Q2 25 | — | $0.47 | ||
| Q1 25 | — | $0.46 | ||
| Q4 24 | — | $0.41 | ||
| Q3 24 | — | $0.35 | ||
| Q2 24 | $0.22 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $136.9M | $362.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-122.8M | $270.7M |
| Total Assets | $172.2M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | $136.9M | $471.1M | ||
| Q3 25 | $180.2M | $232.9M | ||
| Q2 25 | — | $345.2M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $243.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | $354.5M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | $-122.8M | $266.0M | ||
| Q3 25 | $-82.3M | $255.1M | ||
| Q2 25 | — | $240.9M | ||
| Q1 25 | — | $237.9M | ||
| Q4 24 | — | $227.9M | ||
| Q3 24 | — | $235.4M | ||
| Q2 24 | $81.5M | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $172.2M | $4.1B | ||
| Q3 25 | $208.8M | $4.0B | ||
| Q2 25 | — | $4.1B | ||
| Q1 25 | — | $4.0B | ||
| Q4 24 | — | $4.0B | ||
| Q3 24 | — | $4.0B | ||
| Q2 24 | $373.4M | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.3M | $12.9M |
| Free Cash FlowOCF − Capex | — | $12.4M |
| FCF MarginFCF / Revenue | — | 46.0% |
| Capex IntensityCapex / Revenue | 0.0% | 1.8% |
| Cash ConversionOCF / Net Profit | — | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | — | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | $-48.3M | $46.5M | ||
| Q3 25 | $-36.2M | $11.4M | ||
| Q2 25 | — | $13.5M | ||
| Q1 25 | — | $9.7M | ||
| Q4 24 | — | $39.8M | ||
| Q3 24 | — | $12.9M | ||
| Q2 24 | $116.3M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | — | $43.2M | ||
| Q3 25 | — | $10.8M | ||
| Q2 25 | — | $12.8M | ||
| Q1 25 | — | $8.3M | ||
| Q4 24 | — | $13.7M | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | — | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | — | 178.3% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 53.6% | ||
| Q1 25 | — | 35.7% | ||
| Q4 24 | — | 65.6% | ||
| Q3 24 | — | 34.2% | ||
| Q2 24 | — | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | 0.0% | 13.7% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 6.5% | ||
| Q4 24 | — | 125.3% | ||
| Q3 24 | — | 29.4% | ||
| Q2 24 | 0.0% | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | — | 6.26× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.70× | ||
| Q1 25 | — | 1.24× | ||
| Q4 24 | — | 5.61× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | 2.36× | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
